Skip 
Navigation Link

1215 South Walnut Ave.
Demopolis, AL 36732 map map 

Access to Care: 800.239.2901

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
U.S. Better Able to Tackle Health Emergencies: ReportFirst Opioid Lawsuit Targeting Pharmacy Benefit ManagersMost Doctors' Offices Don't Offer Flexibility for UninsuredSafety Info for Opioids Found LackingNonoptimized Drug Therapy Costs More Than $500 Billion AnnuallyFDA Cracks Down on Caffeine-Loaded SupplementsCigarette Tax Hike Could Ease Poverty for Millions Worldwide: StudyCDC: Aggressive Action Needed to Contain Antibiotic ResistanceCould Medical Pot Help Curb the Opioid Abuse Crisis?Medical E-Records Not Without Risks: StudyHealth Groups Sue FDA to Speed Review of E-CigarettesEHR Usability Contributes to Possible Patient Harm EventsAHA: Solving the Dilemma of Not Enough HeartsUnchecked Air Pollution a Death Sentence for Millions: StudyPersonal Health Info Found in Recycling at Five HospitalsTask Force Issues Stronger Skin Cancer Prevention GuidelinesFDA Considers Lowering Nicotine Levels in CigarettesDoctors Facing Challenge to Help Needy While Protecting PracticesPharmacists Encouraged to Learn More About Herbal SupplementsBan Menthols to Help Some Smokers QuitStem Cell Clinics Pitch Pricey, Bogus 'Cures' for Knee PainMany Americans Think Docs Order Too Many Tests, MedsIs Herbal Drug Kratom a Health Friend or Foe?Early Studies Often Show Exaggerated Treatment EffectStrong Tobacco Laws May Weed Out Vapers, TooUnderstanding Rx Nonadherence Can Improve AdherenceBystander Use of Defib Device Doubles Chances of Surviving Cardiac ArrestNew Research Debunks Two Medical Marijuana MythsTake Early Clinical Trials With a Grain of SaltCould Hackers Target Heart Devices?Protecting Your Electronic Health RecordsAfter Another Shooting Tragedy, 'Stop the Bleed' Kits Urged for SchoolsPatients Want Physicians to Have Greater ConnectivityYour Tax Dollars Fund Research on Hundreds of New MedsFour Best Practices Outlined to Prevent Health Care CyberattacksMany Patients Know Too Little About Their MRI, CT Scans: StudyUnsafe Water Found in Faucets Across the U.S.Health Tip: Prevent Exposure to LeadHealth Tip: Online Pharmacies You Should AvoidDon't Count on an American to Do CPRPoll: Personal Beliefs Shouldn't Allow Doctors to Refuse to TreatFDA Says U.S. Will Now Produce Critical MRI ComponentPicking a New Primary Care DoctorUber, Lyft Rides May Not Help Boost Doc Visits for Poorer Patients2018 Immunization Schedule Issued for U.S. ChildrenA Hidden Source of 'Superbugs' in Hospitals?2018 Immunization Schedule Issued for U.S. AdultsTop Three Challenges Identified for Pharmacists in 2018Responding to Opioid Crisis, FDA Puts More Restrictions on ImodiumMonkey Deaths Prompt FDA Probe, New Controls on Animal Research
Questions and AnswersVideosLinksBook Reviews
Related Topics

Health Insurance
Healthcare

FDA Seeks to Speed Development of 'Regenerated' Organs for Medical Use

HealthDay News
by -- E.J. Mundell
Updated: Nov 16th 2017

new article illustration

THURSDAY, Nov. 16, 2017 (HealthDay News) -- Using stem cells to grow new heart tissue, and even whole organs, used to be the stuff of science fiction.

But the field of "regenerative medicine" is a reality now -- and the U.S. Food and Drug Administration has its eye on it, the agency's head said Thursday.

"In the last decade, we've seen improbable advances that hold out great hope for patients," FDA Commissioner Dr. Scott Gottlieb said in an agency news release. "I believe that with the ability to facilitate the regeneration of parts of the human body, we're bearing witness to the beginning of a paradigm shift in the practice of medicine."

For example, over the past few years scientists and physicians have developed tissue-engineered skin for transplant; bladders grown from a patient's own cells; and tissues grown to repair ailing hearts or failing knees, according to the U.S. National Institutes of Health.

But Gottlieb said that along with all this good comes the bad. Companies seeking to exploit consumers are already popping up across the United States -- stem cell "clinics" promising pricey cures that they can't deliver to desperate patients.

"The rapid growth and promise of this field has increasingly sowed the ground for the entry of some unscrupulous actors, who have opportunistically seized on the clinical potential of regenerative medicine to make deceptive claims to patients about unproven and, in some cases, dangerous products," Gottlieb said.

"By exploiting the lack of consumer understanding of this area, as well as the fear and uncertainties posed by the diseases these bad actors claim to treat, they're jeopardizing the legitimacy and advancement of the entire field," he explained.

So, Gottlieb says his agency is rolling out a new "regulatory framework" aimed at encouraging and speeding legitimate development of regenerative therapies that do work, while stamping out firms offering bogus treatments.

He said the FDA intends to promote the "least burdensome" rules for companies big and small that are seeking to develop new therapies, "while ensuring patient safety."

"Our policy will allow product manufacturers that time to engage with the FDA to determine if they need to submit a marketing authorization application and, if so, seek guidance on how to submit their application to the FDA for approval," Gottlieb said.

The new rules are in keeping with provisions from the 21st Century Cures Act, passed by Congress in December. That legislation earmarked $6.3 billion in funding, mostly for the U.S. National Institutes of Health, towards groundbreaking medical research.

According to Gottlieb, the bottom line is to allow patients "access to safe and effective regenerative medicine products as efficiently as possible. We are also committed to making sure we take action against products being unlawfully marketed that pose a potential significant risk to their safety."

More information

There's more on regenerative medicine at the U.S. National Institutes of Health.